avibactam, relebactam, and vaborbactam are devoid of activity against class D OXA β-lactamases, which illustrates the challenge in designing such compounds. Sulbactam, which is an "older" or legacy BLI, effectively permeates the outer membrane and reaches the periplasmic compartment of Acinetobacter. However, sulbactam fails to inhibit class D OXA β-lactamases, additional evidence of formidable scientific intricacy of the field. This challenge led us to explore the effects of introduction of a nitrile functional group onto the DBO core. Unlike avibactam and relebactam, WCK 4234 (compound 3), possessing a nitrile side chain (R 1 ) at the C2 position of the DBO (Figure 1 ), demonstrates expanded activity against class D OXA β-lactamases, including OXA-23 and OXA-51 expressed in A. baumannii, while maintaining activity against class A and C β-lactamases. 14 The structure-activity relationships (SAR) that prompted the design of compounds 1-3 are presented herein. Furthermore, we evaluate 1-3 and two DBO comparators, avibactam and relebactam ( Figure 1 , chemical structures), to gain mechanistic insights into their inhibitory activity against representative serine class A, C, and D β-lactamases using steady-state kinetics and mass spectrometry. As a result of these studies, KPC-2 and OXA-24 were chosen for X-ray crystallography analysis to define, on an atomic level, the nature of the inactivation mechanism. Finally, the abilities of cefepime-2 (WCK 5222) and meropenem-3 (WCK 5999) combinations were evaluated in susceptibility studies and mouse models of infection. Our data show that cefepime-2 and meropenem-3 offer promise against pathogens possessing β-lactamases from multiple classes. Notably, the cefepime-2 combination has completed two phase I clinical trials (NCT02707107, NCT02532140), and another phase I clinical trial is actively recruiting participants (NCT02942810).
RESULTS AND DISCUSSION

Synthesis of a Novel Class of DBOs.
Starting with a DBO scaffold, a pathway to identify compounds with activity against Gramnegative PBP-2 and β-lactamases led to the evolution of this novel bicyclo hydrazide (BCH) series. 11 The key medicinal chemistry challenge involved in identifying a side chain (R 1 ) at the C-2 position of the DBO core that was able to penetrate the periplasmic space of Gramnegative bacteria and access PBP targets on the cytoplasmic membrane. After developing SAR with linear-chain and cyclic amines, 15 a cyclic secondary amine was employed on the acyl hydrazide to obtain compounds with high affinity binding for the PBP-2 of Enterobacteriaceae, P. aeruginosa, and A. baumannii. 11 Thus, the hydrazide as an R 1 side chain bearing a free amine at the appropriate length from the C-2 position of the DBO core was found to be essential for antibacterial potency. Enhancement of antibacterial activity was further achieved by chiral separation of the isomers of the racemic secondary cyclic amine. SAR generated the lead compounds 1 16 and 2 17 and bearing pyrrolidine and piperidine side chains, respectively ( Figure 2A ). These compounds demonstrated a targeted antibacterial profile encompassing Enterobacteriaceae and nonfermenter organisms. 11 To obtain a DBO that demonstrates expanded antimicrobial activity against A. baumannii producing class D carbapenemases, OXA-23 and OXA-51, while maintaining activity in Gram negatives producing class A and C β-lactamases, 14 we next examined the properties of the nitrile group in the literature. 18 Because nitrile bonds are polarized, they act as hydrogen acceptors and form hydrogen bonds with amino acids and water and can thus bind to a protein backbone. Furthermore, the strong dipolar nature of the nitrile permits it to act as a hydroxyl or carboxyl bioisostere. The introduction of nitrile additionally reduces the clogP of the molecule thereby reducing its lipophilicity and thus improving the chances of penetration of the porin channels in Gram-negative organisms. The nitrile group is not readily metabolized, which could be advantageous. Importantly, the nitrile reduces the steric bulk of the R 1 substituent of DBOs such as avibactam and thus could yield a better fit into sterically constrained active sites, such as the class D OXA β-lactamase's active site. On the basis of our observations, we replaced the amide functionality of avibactam with a nitrile, generating compound 3 ( Figure 2B ).
Compound 3 is a Highly Potent Inactivator of Class A, C, and D β-Lactamases.
Compound 3 inhibited all β-lactamases tested with K i app values ranging from 0.1 to ≤8 μM (Table 1 ). Testing KPC-2, 3 possessed the highest acylation rate (k 2 /K value) by nearly 9-fold compared to relebactam. Additionally, 3 was the only DBO capable of acylating OXA-23, OXA-24/40, and OXA-48. The highest k 2 /K value obtained was with OXA-48 and 3, 6.4 ± 0.6 × 10 5 M −1 s −1 .
The rate (k off ) at which the DBOs deacylate (recyclize) the β-lactamases to reform active DBO was also determined ( Table 1 ). The rank order of 3's recyclization after inhibition was as follows: PDC-3 ≫ ADC-7 > OXA-48 > OXA-23 > OXA-24/40 > KPC-2. After inhibition by 3, PDC-3 recovered the ability to hydrolyze nitrocefin the fastest.
The k off values correspond to the residence time half-lives as listed in Table 1 . Comparing all of the k off values, avibactam was the DBO with the lowest k off values. The β-lactamases/DBO combination with the longest residence time half-life was OXA-24/40 and avibactam at 1,823 min. 19 The turnover number (k cat /kinact = t n ) at 24 h or the number of inhibitor molecules hydrolyzed before the β-lactamase is inactivated was also measured (Table 1) . KPC-2 possessed a k cat /k inact value of 1 for all the DBOs tested. In contrast, ADC-7 demonstrated turnover of all of the DBOs; t n = 6 at 24 h. Although insignificant in terms of the bacterial cell cycle, the basis for this catalytic ability is being investigated. For the relative t n values to be put into context, the t n of KPC-2 for clavulanic acid is 2,500 at 15 in this study, we performed timed mass spectrometry with β-lactamases that were incubated with the DBOs at an equimolar ratio for 5 min and 24 h.
The reaction intermediates between KPC-2 and either 1 (+378 ± 5 amu), 2 (+392 ± 5 amu), 3 (+247 ± 5 amu). or relebactam (+349 ± 5 amu)-formed adducts did not undergo a secondary chemical reaction; notably, desulfation was also not observed (Table 2) . However, with avibactam, loss of the sulfate (-97 ± 5 amu) was demonstrated with KPC-2 after a 24 h incubation. For ADC-7, the full adducts were detected with all DBOs, except a minor loss of the sulfate (-80 ± 5 amu) was detected with 3 and avibactam at both 5 min and 24 h (Table  2) . Morever, hydrolysis of 1-3 and avibactam occurred as apo-ADC-7 (40,639 ± 5 amu) was noted; only relebactam was not hydrolyzed under these conditions. These data are consistent with the k cat /k inact values obtained for ADC-7 at 24 h (Table 1) .
During protein purification, two isoforms (40,654 ± 5 and 40,785 ± 5 amu) of the PDC-3 β-lactamase were detected. We attribute this finding to a "ragged" N-terminus (different amino acids at the N-terminus) that occurs when proteins are overexpressed. As with the ADC-7 β-lactamase, a minor loss of the sulfate side chain (-80 ± 5 amu) was observed with PDC-3 β-lactamase after incubation with 3 and avibactam at both 5 min and 24 h. When the OXA-23, OXA-24/40, or OXA-48 β-lactamases were incubated with 3, three peaks were obtained; the major peak identified was the full adduct (+246 ± 5 amu) with two minor peaks corresponding to apoenzyme and the enzyme-DBO complex minus the sulfate (+166 ± 5 amu) at both 5 min and 24 h. In the reaction of OXA-48 β-lactamase with avibactam, only the loss of the sulfate (-80 ± 5 amu) was distinguished at 5 min. At 24 h, the full avibactam adduct (+265 ± 5 amu) was observed with the OXA-48 β-lactamase.
Interestingly, different mass adducts were discerned: a −80 amu with 3 and avibactam with the class C and D β-lactamases and −97 amu adduct with avibactam and KPC-2 ( Figure 3B ).
Compound 3 undergoes a different desulfation mechanism (reaction) compared to the one observed with avibactam and KPC-2 as a −80 amu peak is detected corresponding to hydrolytic loss of SO 3 , which is speculated to result in the hydroxylamine. The significance of this finding is being further explored.
Interactions of 1-3 with β-Lactamases are Reversible.
To confirm the reversibility of 1-3, an acyl-transfer experiment was conducted using KPC-2 as the donor β-lactamase and TEM-1 as the recipient β-lactamase. The donor β-lactamase was preincubated with the DBO at an equimolar ratio. Then, the recipient β-lactamase was added to the reaction, and at 15 s and 5 min, the reactions were terminated and ESI-MS was conducted. Avibactam was previously shown to transfer slowly from TEM-1 to CTX-M-15 with a minor CTX-M-15-avibactam population observed at 2 min. 5 The maximum transfer of avibactam from TEM-1 to CTX-M-15 was observed at 30 min. Here, after complete inactivation (1 min incubation time) by an equimolar ratio of KPC-2 to compound 1, 2, or 3 was obtained; then, an equimolar amount of TEM-1 was added, and the reactions were terminated by the addition of 1% acetonitrile and 0.1% formic acid. The mass spectrometry results implied that 1-3 are reversible ( Figure 3C ). Within 15 s, 3 transferred to TEM-1, whereas for 1 and 2, 5 min was required. Compounds 1-3 transfer faster than avibactam, which directly correlates to the k off values observed (Table 1) .
KPC-2 β-Lactamase Crystal Structures with 1-3.
The crystal structures of the DBO inhibitors 1-3 bound to KPC-2 were obtained via soaking experiments and using cocrystallization ( Figure 4 , Figure S1 , and Table S1 ). The inhibitors were refined with 100% occupancy yielding low B-factors for the inhibitors (Table S1) ; this indicates full occupancy of the inhibitors in agreement with the appearance of strong inhibitor electron density. With each complex structure determined via these two methods, unexpected differences were obtained for the 1 and 2 structures: we observed desulfation of these two DBO inhibitors when cocrystallized but not when soaked into the KPC-2 crystals ( Figure S1 ); these differences were not observed for 3. Desulfation of a similar DBO, avibactam, by KPC-2 was previously also seen and found to be a slow process. 21 We subsequently probed the KPC-2-mediated desulfation of these two DBOs using mass spectrometry and also observed this phenomenon at lower pH values similar to the pH of the crystallization conditions ( Figure S1 ). Because of the nonphysiological pH and slow rate of this reaction, our discussion will therefore focus on the structures obtained by soaking.
The three DBO inhibitors adopt a similar conformation when bound covalently to S70 in the active site of KPC-2. The 6-membered ring of the DBO adopts a chair conformation with the sulfate moiety occupying the carboxylate binding pocket of the active site. The sulfate moiety in 3 was observed to be in two conformations ( Figure 4B ), whereas this moiety in the other two DBOs adopted a single conformation. In all three structures, the sulfate makes hydrogen bonds with T235, T237, and S130 and is positioned ~4.5 Å from R220. The carbonyl oxygen in each of the three DBO complexes is located in the oxyanion hole formed by the backbone nitrogens of S70 and T237. The R-group moieties that distinguish the inhibitors from each other make different interactions with KPC-2. The R-group nitrile moiety in 3 makes a hydrogen bond with N132, whereas the R-groups in 1 and 2 make interactions with N132, the deacylation water (W#1), and some additional interactions with other water molecules ( Figure 4B ). The R-group in 2 also makes a hydrogen bond with the backbone oxygen of C238; this interaction is not observed in the avibactam:KPC-2 complex 22 nor in the relebactam:AmpC complex. 10 The three DBO inhibitor structures are all in a very similar position and orientation as shown by superpositioning ( Figure 5 ). These positions and orientations are very similar to that of avibactam bound to KPC-2; the ring structures of these DBOs all adopt the chair conformation ( Figure 5 ). The KPC-2 protein in the DBO complexes also adopts a similar conformation except for residue W105 for which there is considerable conformational variability compounded by some structures even having two alternative conformations for this residue ( Figure 5 ). We show molecule B of the 3:KPC-2 complex in the superpositioning to further illustrate this point ( Figure 5 ). The superpositioning also revealed a subtle clustering of the DBO ring positions with 1 and 2 in one cluster, the 3 molecule A and B in a second cluster, and avibactam in a third slightly different orientation ( Figure 5 ). These differences are likely due to the different R-group substituents.
OXA-24/40-Compound 3 Crystal Structure.
We next analyzed a structure of 3 bound to the OXA-24/40 β-lactamase ( Figure 6A and B). Overall, 3 binds to the OXA-24/40 β-lactamase in a similar fashion to that when bound to KPC-2 except for a few changes mostly due to differences between the protein. Compound 3 is covalently bound to the catalytic S81 residue. Compound 3's sulfate moiety interacts with R261, S219, K218, and S128. The carbonyl oxygen atom is situated in the oxyanion hole as in KPC-2. Unlike KPC-2, the nitrile moiety of 3 is not directly interacting with the protein.
In the 3-OXA-24/40 β-lactamase complex, we do not observe carboxylation of K84 as was observed in OXA-24/40 complexes bound to either penicillanic acid sulfones 23 or boronic acid inhibitors. 24 Instead, this position is filled by the presence of a chloride ion observed in two alternate positions with occupancies of 0.63 and 0.37 (labeled Cl1 and Cl2, respectively, in Figure 6C ). This chloride ion is present due to the HCl used for the pH of the cacodylate buffer. Superpositioning of the 3:OXA-24/40 structure with that of the avibactam:OXA-24/40 complex 25 indicates that avibactam and 3 have a very similar binding mode including a chair conformation of the DBO ring. The DBO inhibitors sit on the inner side of the active site bridge formed by residues M223 and Y112. The avibactam: OXA-24/40 complex has neither a carboxylated K84 nor a bound chloride ion; instead, it has CO 2 bound at this position ( Figure 6C ). It is interesting to note that the class D OXA β-lactamases were found to be inhibited by chloride ions that compete for the carboxylation of 
Inhibitory Activity of DBOs against Bacterial Cells.
Compound 3, avibactam, and relebactam are BLIs. Compounds 1 and 2 can also inhibit β-lactamases but are additionally able to inactivate PBPs and serve as BLEs. 11 As a result, the DBOs either alone or in combination with either cefepime or meropenem were tested in whole cell assays to obtain minimum inhibitory concentrations (MICs). The panel of isolates selected included a set of isogenic strains expressing a single β-lactamase and clinical isolates of Enterobacteriaceae producing bla KPC-2 or bla OXA-48 , ceftazidime-avibactamresistant P. aeruginosa, and A. baumannii producing bla and/or bla . These isolates represent some of the most difficult to treat Gram-negative pathogens, and they produce the most challenging β-lactamases to inhibit.
Isogenic E. coli DH10B with pBR322-catI-bla KPC-2 and A. baumannii Δbla ADC with pWH1266 bla or bla OXA-24 demonstrated MICs of >16 μg/mL for cefepime and ≥8 μg/mL for meropenem (Table 3 ). All MICs of cefepime or meropenem combined with all five DBOs (using fixed concentrations of DBOs of 4 and/or 8 μg/mL) against E. coli DH10B with pBR322-catI-bla KPC-2 were reduced to ≤0.12 μg/mL. Only cefepime combined with 3 restored susceptibility for A. baumannii Δbla ADC with pWH1266 bla OXA-23 (MIC = 2 μg/ mL). A. baumannii Δbla ADC with pWH1266 bla was resistant to all combinations tested.
A panel of clinical isolates of Klebsiella pneumoniae that carry either bla KPC-2 or bla including colisitin susceptible (ColS) and colistin resistant (ColR) strains and other Five clinical strains of P. aeruginosa from an archived collection previously found to be resistant to ceftazidime-avibactam were also tested. 28 Combination of cefepime and 1 or 2 at 8 μg/mL restored cefepime susceptibility (MICs ≤ 0.12-0.5 μg/mL) to that of some of these highly drug resistant strains (Table 3) . PBP-2 inhibition and BLE activity of 1 and 2 most likely provided this advantage against P. aeruginosa. 11
The DBOs were tested against a panel of clinical isolates of A. baumannii that possess either bla or bla or both bla OXA-23 and bla (Table 3) . Compounds 1-3 demonstrated some activity against these strains when combined with cefepime. However, against dual OXA-carbapenemase-expressing strains, most combinations showed high MICs. Given that 3 is a potent inhibitor of OXA-23 and OXA-24/40, limited penetration of cefepime and/or 3 is a possible cause of the lack of efficacy in these strains. Overall, the meropenem-3 combination was more active against A. baumannii with bla OXA-23 and/or bla , which is in agreement with another study. 14 For determining the cause of the higher MICs for the β-lactam-DBO combinations against A. baumannii, A. baumannii ATCC 17978 was used as the parent strain, and different efflux pump components were knocked-out as well as blhA (β-lactam hyper susceptibility), which is a determinant of intrinsic β-lactam resistance that is also involved in cell division.
AdeABC, AdeFGH, AdeIJK, and AcrA systems are the major resistance-nodulation-division (RND) efflux systems in Acinetobacter. These systems are three-component efflux pumps where AdeA, AdeF, AdeI, and AcrA are the membrane fusion protein (MFP), AdeB, AdeG, and AdeJ are the multidrug transporter, and AdeC, AdeI, and AdeK are the outer membrane protein (OMP). AcrR is the transcriptional regulator of the AcrA RND efflux pump. The AdeB and AdeJ efflux pump components may have some contribution to cefepime efflux as when the corresponding genes were deleted, susceptibility was increased (Table S2) . Overall, the strains were all susceptible to single agents as well as the combinations.
Cefepime-2 and Meropenem-3 Were Tested against MDR A. baumannii in Murine Models of Peritonitis and Neutropenic Lung Infection.
The protective doses (PD 50 and PD 90 , i.e., the dose of antibiotic that protects 50 or 90% of the infected mice, respectively) were determined for cefepime-2 and meropenem-3 using a murine peritonitis model. Mice were intraperitoneally infected with one of three different A. Table 4 . The mice were treated with cefepime, cefepime-2, meropenem, meropenem-3, tigecycline, or colistin, and survival patterns were monitored for 7 days. The PD 50/90 for cefepime-2 ranged between 50 and 100 mg/kg for cefepime and 23.23-52.30 mg/kg for 2 (Table 4) . Remarkably, the cefepime-2 PD 50/90 provides just 25% exposure compared to the exposures at the selected clinical dose. 29, 30 For meropenem-3, the PD 50/90 's were 25-50 mg/kg for meropenem and 16.30-66.17 mg/kg for 3 (Table 4) . Tigecycline, although employed at supra-therapeutic doses (6.25 mg/kg administered as two doses), failed to protect infected mice (Table 4) . Considering the colistin MIC values of 0.5-1 μg/mL, colistin appropriately exhibited low PD 50/90 values ( Table 4) . 31 For the in vivo eradication efficacy of cefepime-2 and meropenem-3 to be determined, a neutropenic lung infection model was used in which mice were intranasally infected with a clinical isolate of A. baumannii SL04 carrying bla OXA-23 and bla . The MICs for this isolate are as follows: cefepime, 256 μg/mL; 2, ≥512 μg/mL; cefepime-2, 32 μg/mL; imipenem, 64 μg/mL; meropenem, 64 μg/mL; meropenem-3, 8 μg/mL; colistin, 2 μg/mL; and tigecycline, 4 μg/mL. Thus, the MIC of cefepime was reduced by 8-fold when in combination with 2. Two hours post infection, mice were treated by q2h dosing for 24 h by a subcutaneous route. Three hours post last dose (i.e., 27 h postinfection), the murine lungs were removed, and colony forming units (CFUs) were determined. Treatment of infected mice with cefepime (50 mg/kg), meropenem:cilastatin (25-25 mg/kg), and imipenem:cilastatin (25-25 mg/kg) revealed a 0.67-1.31 log increase in bacterial burden as compared to the 2 h count ( Figure 7A ). Treatment with cefepime-2 (50-8.33 mg/kg) resulted in a 3 log kill ( Figure 7B ). Notably, the addition of 2 to cefepime enhanced the bactericidal action of cefepime even at very low dose of 50 mg/kg. 32 Similarly, the addition of 3 at 4.68 mg/kg to meropenem:cilastatin (25-25 mg/kg) resulted in a 2.47 log kill ( Figure 7B ). Conversely, relebactam at 18.75 mg/kg combined with imipenem:cilastatin at 25 mg/kg resulted in a 0.86 log increase in CFUs ( Figure 7B ). It is important to note that A. baumannii NCTC 13301, SL46 and SL04 produce OXA-23 and OXA-51, which are not inhibited by 2. Even with higher MICs, the cefepime-2 combination provided potent in vivo efficacy against these strains based on its BLE mechanism of action. 33 The most significant feature of the BLE mechanism is the augmentation of the pharmacodynamic action of the partner β-lactam antibiotic. In addition, BLEs enhance the arsenal of agents required to overcome β-lactamases. A further challenge in designing novel BLIs also stems from imparting them with structural features, which facilitate their efficient penetration into MDR Gram-negative pathogens. Many contemporary MDR pathogens express effux pumps as well as mutations in the genes encoding various outer membrane proteins. These mechanisms could impact the uptake of some newer BLIs that show potent activity against inhibitor-resistant enzymes. Compound 3, by virtue of its potent BLI activity for OXA-carbapenemases and ease of penetration, restores the efficacy of meropenem against MDR A. baumannii. 31
CONCLUSIONS
Here, we revealed the biochemical activity of three novel DBOs, compounds 1-3 against some of the most challenging β-lactamases in Gram-negative bacteria (i.e., KPC-2, PDC-3, ADC . We also verified in vivo efficacy of cefepime-2 and meropenem-3. Compound 3 was found to extend the kinetic inhibitory profile of DBOs to OXA carbapenemases while maintaining class A and C activity. Compounds 1 and 2 demonstrated increased potency against class C β-lactamases compared to avibactam and relebactam. Compounds 1 and 2 are unique DBOs in that they also target PBPs of many Gram-negative pathogens and have BLE activity. Thus, they work synergistically when paired with an appropriate β-lactam antibiotic and overcome β-lactamase-mediated resistance without the need to inhibit multiple β-lactamases. The addition of compounds 1-3 to our armamentarium would be highly beneficial as the clinically available β-lactams and β-lactam-BLI combinations are not effective against these refractory Gram-negative pathogens. Finally, compounds 1-3 exemplify two divergent strategies in rejuvenating β-lactam antibiotics.
EXPERIMENTAL SECTION
Compound Characterization.
Nuclear magnetic resonance spectra were recorded on a Mercury 400 MHz (Varian Inc.) or 500 MHz (Bruker). The mass spectra were recorded on a TQD mass spectrometer (Waters Corp.) using the electrospray ionization technique. Elemental analysis was conducted on Vario-Micro cube elemental analyzer (Elementar). Water content was determined using Karl-fisher titration method. The purity (>95%) of all of the compounds was established using the high-pressure liquid chromatography method with 5 μm particle size C18 columns (Bonna Agela Technologies for 2 and YMC Technologies for the remaining compounds) maintaining solution at 10 °C.
Synthesis of 1 and 2.
Figure 2A represents construction of BCH backbone intermediate 1b and 2b as a result of coupling of corresponding chiral acid hydrazide 1a or 2a with sodium salt of DBO nucleus represented by A by using EDC·HCl as a coupling agent in water (~87%, n = 1 and 2).
Subsequent catalytic hydrogenation (10% Pd/C catalyst) furnished hydroxyl intermediate (1c, n = 1 or 2c, n = 2) in quantitative yield, which was subjected to sulfonation reaction immediately by using sulfurtrioxide pyridine complex to afford sulfonated intermediate. The sulfonated intermediate was isolated in the form of tetrabutylammonium salt 1d (60%, n = 1) or 2d (87%, n = 2). Finally, removal of the N-Boc group and tetrabutyl ammonium salt was achieved in one step using excess TFA at 0-5 °C. Compounds were purified by crystallizing in aqueous isopropanol to furnish 1 (1e, n = 1, 60%,), or 2 (2e, n = 2, 80%).
Synthesis of 3.
Figure 2B represents the synthesis of 3, 34 where the sodium salt of the DBO core (A) was converted into the mixed anhydride by first treating the sodium salt with triethylamine hydrochloride in dichloromethane and reacting the resulting compound with pivaloyl chloride in the presence of a base triethylamine at 0-5 °C, to obtain the mixed anhydride, which was as such reacted with a 25% aqueous solution of ammonia in water at -20 °C to obtain the amide (3a) as an off-white solid after workup and purification. The amide (3a) was dehydrated with trifluoroacetic anhydride in the presence of triethylamine in dichloromethane at -5 °C to RT to obtain the cyano compound (3b), which was debenzylated with 10% Pd/C (50% wet) in a 1:1 (v/v) mixture of DMF:DCM (v/v) under a hydrogen atmosphere (50-55 psi) to obtain the hydroxyl compound (3c). This compound was then immediately sulfated with the DMF:SO 3 complex to obtain the sulfate, which was isolated as its tetrabutylammonium salt (3d) by reacting with tetrabutylammonium acetate. The tetrabutylammonium salt (3d) was converted to 3 by passing the salt through a column filled with Indion 225 sodium resin. Compound 3 was obtained as a white solid by lyophylization of the aqueous solution and recrystallization of the dry powder from a mixture of isopropanol and water. 1, 168.9, 166.1, 58.4, 57.7, 47.0, 46.9, 45.3, 40.1,28.7, 20.6, 18.4; IR (cm -1 ) 3568, 1746 IR (cm -1 ) 3568, , 1709 IR (cm -1 ) 3568, , 1676 IR (cm -1 ) 3568, , 1279 IR (cm -1 ) 3568, , 1234 IR (cm -1 ) 3568, , 1015 3, 168.6, 167.3, 154.9, 135.4, 129.2, 128.7, 128.5, 80.1, 78.2, 59.1, 57.7, 47.7, 45.5, 44.5, 40.8, 28.3, 27.5, 24.0, 20.6, 17.4 (1.5 L) under stirring at 30 °C, and after 1 h, triethylamine (70 mL,0.503 mol) was added followed by dropwise addition of pivaloyl chloride (74 mL, 0.603 mol) at 0-5 °C and stirring continued further for 1 h. The reaction mixture was cooled to -20 °C, and aqueous ammonia (103 mL, 1.51 mol) was slowly added. After 30 min of stirring at -20 °C, water (1.5 L) was added, and the two layers separated. The aqueous layer was extracted with fresh DCM (750 mL). The combined organic layer was dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure (200 mmHg). The concentrate was diluted with n-butyl chloride (450 mL), and the mixture was stirred for 2 h. The separated solid was filtered, and the solid residue was washed with fresh n-butyl chloride (100 mL). The solid was dried under reduced pressure (4 mmHg (32 g, 0. 124 mol) in a mixture of DMF:DCM (1:1, 160 mL:160 mL) containing 10% Pd/C (4.6 g, 50% wet) was hydrogenated at 50-55 psi for 2 h at 25 °C. The resulting mixture was filtered through a Celite pad, and the residue was washed with DMF:DCM (1:1, 25 mL:25 mL). The solvent from the combined filtrate was evaporated under reduced pressure to obtain the product as an oil, which was used as such for the next reaction without further purification (20.66 g; ~100% yield). A small quantity was purified by column chromatography over silica gel (60-120 mesh) and using 30-35% v/v (20.66 g, 0.124 mol) in DMF (160 mL) was added the DMF-SO 3 complex (22.8 g, 0.149 mol) in one portion, and stirring was continued further. After 1 h of stirring, to the resulting reaction mass was slowly added a solution of tetrabutylammonium acetate (48.6 g, 0.161 mol) in water (160 mL). After 1 h of further stirring, the solvent from the reaction mixture was evaporated under reduced pressure to obtain an oily residue. The oily mass was coevaporated with xylene (2 × 200 mL) to obtain a thick mass. This mass was partitioned between dichloromethane (320 mL) and water (320 mL). The organic layer was separated, and the aqueous layer was reextracted with dichloromethane (160 mL). The combined organic extracts were washed with water (3 × 160 mL) and dried over anhydrous Na 2 SO 4 , and the solvent was evaporated under reduced pressure at 35 °C. The residual oily mass was triturated with ether (3 × 160 mL) each time the ether layer was decanted, and finally, the residue was dried under reduced pressure to obtain the product (3d) as a pale yellow oil: 52. (1200 g) and was eluted using 10% THF in water. The pure fractions were collected, and THF was evaporated under reduced pressure. The aqueous solution was extracted with ethyl acetate (5 × 250 mL), treated with charcoal for decolorization, and filtered. The filtrate was lyophilized, and the powder obtained was recrystallized using isopropanol:water to obtain the product (3) 
Synthesis of (2S,5R)-6-Sulfooxy-7-oxo-2-[((3R)-pyrrolidine-
3- carbonyl)hydrazinocarbonyl]-1,6-diazabicyclo[3.2.1]octane, 1 (1e).-Step 1: (2S, 5R)-6-Benzyloxy-7-oxo-2-[((3R)-N-Boc-pyrrolidine-3-carbonyl)hydrazinocarbonyl]-1,6- diazabicyclo
Plasmids and Strains.
The cloning and/or origins for bla KPC-2 , bla PDC-3 , and bla ADC-7 genes for susceptibility testing and bla KPC-2 , bla PDC-3 , bla ADC-7 , bla , and bla OXA-24/40 genes (missing the nucleotides encoding their signal peptides) for protein expression were described in the following references. 11, 20, [35] [36] [37] The methods for the generation of the A. baumannii ATCC17978 knockout strains have been previously described. 38 For MIC analysis, the bla OXA-48 gene was cloned into the pBC SK (−) vector by amplifying the bla OXA-48 coding and upstream promoter regions from K. pneumoniae CAV1543 containing bla , sequence verified, and transformed into the E. coli DH10B. 19 For large-scale protein expression, the bla OXA-48 gene without its leader peptide sequence was cloned into the pET24a(+) vector using NdeI and XhoI restriction sites and electroporated into E. coli DH10B. The resulting construct was sequence verified and transformed into E. coli BL21(DE3) cells for protein expression and purification.
For MIC testing, as OXA-23 and OXA-24/40 do not express well in an E. coli background, presumably due to codon usage, another expression strategy was utilized. For bla , the bla gene and its upstream ISAba1 was amplified from strain AB0057, and for bla , the bla gene and its upstream XerC/XerD was amplified from strain A. baumannii NM55.
The amplified genes were cloned into the Xba1 site of the modified pWH1266 vector (a vector that replicates in A. baumannii) in which ampicillin resistance was eliminated (Δbla TEM-1 ) by inverse PCR, and an Xba1 site was engineered into the vector. Once the proper sequence was confirmed in the constructs, the clone was transformed into the A. baumannii OM2 clinical isolate. To reduce the ampicillin MIC of the OM2 strain, the native bla ADC gene was knocked out. A 3 kb fragment including the bla ADC gene and ~1 kb flanking sequence upstream and downstream of bla ADC was amplified out of OM2 and cloned into pCR-XL-TOPO. The bla ADC gene in the pCR-XL-TOPO clone was removed by inverse PCR, and a tobramycin resistance gene was put in its place. This plasmid was used to generate the bla ADC knockout. Linearized bla ADC knockout plasmid was electroporated into OM2 cells with selection on tobramycin. Colonies that grew on tobramycin were PCR screened for the tobramycin resistance gene to ensure that they were not breakthrough colonies. PCR using a primer upstream of the area used to make the bla ADC construct and a second primer residing in the tobramycin resistance gene was performed to show integration into the desired location. Finally, PCR to amplify the bla ADC gene was negative, demonstrating that the bla ADC gene was successfully knocked out. Note: The bla ADC knockout of OM2 still contains bla . Numerous attempts to knock out the bla OXA-51 gene were unsuccessful. It is unknown if other β-lactamases are present in OM2.
Protein Purification for Kinetic Assays and Mass Spectrometry.
The purification of KPC-2, ADC-7, PDC-3, and OXA-23 was previously described. 11, 20, 36, 37 OXA-24/40 and OXA-48 were purified according to the following protocols.
The OXA-24/40 β-lactamase was purified as follows. E. coli BL21(DE3) containing the bla OXA-24/40 pET24 (+) construct was grown in SOB containing 50 μg/mL of kanamycin at 37 °C with shaking to achieve an OD 600 of 0.8. IPTG was added to the culture to a final concentration of 0.2 mM, and the culture was grown for three more hours. The cells were centrifuged and frozen at −20 °C. Pellets were thawed and suspended in 50 mM Tris-HCl, pH 7.4 with lysozyme (40 μg/mL), benzonuclease, and 1 mM MgSO 4 . Cellular debris was removed by centrifugation, and the lysate was subjected to preparative isoelectric focusing (pIEF) overnight. The location of OXA-24/40 on the pIEF gel was determined using a nitrocefin (NCF; Becton, Dickinson and Company) overlay. OXA-24/40 was further purified by SEC using a HiLoad 16/60 Superdex 75 column (GE Healthcare Life Science). The OXA-48 β-lactamase was purified from E. coli BL21(DE3) containing the bla OXA-48 / pET24 (+) construct as described above for OXA-24/40.
Steady-State Inhibitor Kinetics.
For determining the inhibitory potential of compounds 1-3 against select class A, C, and D β-lactamases, steady-state inhibition kinetics were conducted using an Agilent 8453 Diode Array spectrophotometer. Class A and C β-lactamases were tested in 10 mM phosphatebuffered saline, pH 7.4, and 50 mM sodium phosphate buffer, pH 7.2 (supplemented with 20 mM sodium bicarbonate) was used for class D β-lactamases. 39 The proposed interactions between β-lactamases and DBOs is depicted in Figure 3A .
As an initial screen for inhibiton, a direct competition assay was performed to estimate the Michaelis constant, K i app , of the inhibitor. If the K i app value was >100 μM, further biochemical analyses were not pursued. We used a final concentration of 50-100 μM (or 3-5 × K m ) of nitrocefin (ncf) as the indicator substrate and nM concentrations of β-lactamase in these determinations. The data were analyzed according to eq 1 to account for the affinity of nitrocefin for the β-lactamase
where [S] is the concentration of nitrocefin.
The second-order rate constant for enzyme and inhibitor complex inactivation, k 2 /K, was measured directly by monitoring the reaction time courses in the presence of inhibitor. A fixed concentration of enzyme, nitrocefin, and increasing nM concentrations of BLI or BLE were used in each assay. Progress curves were fit to eq 2 to obtain the observed rate constant for inactivation (k obs )
where V f is the final velocity, V 0 is the initial velocity, and A 0 is the initial absorbance at wavelength 482 nm. Data were plotted as k obs vs [I] . The k 2 /K values were obtained by correcting the value obtained for the slope of the line (k 2 /K observed) for the use of the K m of ncf for the given enzyme according to eq 3.
The off rate or k off was determined by incubating β-lactamase with DBOs at a concentration of 5× K i app for 30 min. Samples were serially diluted, and hydrolysis of 100 μM nitrocefin was measured. The progress curves were fit to a single exponential decay equation.
Partition ratios (k cat /k inact [where k inact is the rate constant of enzyme inactivation]) at 24 h for β-lactamases with inhibitor were obtained by incubating enzyme with increasing concentrations of inhibitor at room temperature. The ratio of inhibitor to enzyme (I:E) necessary to inhibit the hydrolysis of NCF by >99% was determined.
Mass Spectrometry.
Electrospray ionization mass spectrometry (ESI-MS) of the intact β-lactamases was performed on a Waters SynaptG2-Si quadrupole-time-of-flight mass spectrometer. The Synapt G2-Si was calibrated with sodium iodide using a 50-2000 m/z mass range. This calibration resulted in an error of ±5 amu. After 5 min and 24 h incubation of β-lactamase and inhibitor at a 1:1 ratio, the reactions were terminated by the addition of 0.1% formic acid and 1% acetonitrile. The samples were run using Waters Acquity H class UltraPerformance Liquid Chromatography (UPLC) on an Acquity UPLC BEH C18 1.7 μm, 2.1 × 100 mm column. The mobile phase consisted of 0.1% formic acid in water. The tune settings for each data run are as follows: capillary voltage, 3.2 kV; sampling cone, 30 V; source offset, 30; source temperature, 100 °C; desolvation temperature, 450 °C; cone gas, 50 L/h; desolvation gas, 600 L/h; and nebulizer bar, 6.0. Spectra will be analyzed using MassLynx v4.1. Data presented are the consensus results from 2-3 experiments.
For determining if any resulting adducts (e.g., −80 amu, see Results and Discussion) were mass spectrometry artifacts, samples were rerun using capillary voltages of 1 or 4.5 kV with the other conditions as described above. In addition, the samples were rerun with the sampling cone at 5, 20, 30, 40, 50, 60, or 70 V with the other conditions as described above.
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Acyl Transfer.
To assess if 1-3 recyclize to reform active compound, an acyl-tranfer ESI-MS experiment was conducted using KPC-2 as the donor and TEM-1 as the recipient. Five micromolar KPC-2 was incubated with 1, 2, or 3 at an equimolar ratio for 1 min. Five micromolar TEM-1 β-lactamase was added to the mixture. At the time points of 15 s and 5 min, reactions were terminated and prepared for ESI-MS as described above.
Protein Purification for Crystallography.
KPC-2 was expressed and purified as described previously. 40, 41 The purified KPC-2 protein was concentrated to 10 mg/mL (measured by Bradford assay), aliquoted, and stored at −80 °C until further use for cocrystallization or soaking of the 1, 2, or 3 inhibitors as described below. OXA-24/40 was expressed and purified as previously described. 23
Crystallization of Apo KPC-2 and Soaking of 1-3.
KPC-2 crystals were grown in the same crystallization conditions as described previously, 22 which consists of 20% PEG6000, 100 mM citrate pH 4.0, and 100 mM KSCN, yet 10 mM CdCl 2 was added as a crystallization additive to improve crystallization. The addition of CdCl 2 also favored KPC-2 to crystallize in the P1 spacegroup. The protein concentration for crystallization was 10 mg/mL. The soaking solutions were prepared similarly to crystallization conditions at pH 5.0 with the addition of 10 mM inhibitor (1) (2) (3) . The KPC-2 crystals were soaked for 3 h before being cryo-protected with the soaking solution also containing 20% ethylene glycol and subsequently flash frozen in liquid nitrogen prior to data collection.
Cocrystallization of KPC-2 with 1-3.
Prior to cocrystallization, the KPC-2 protein and each inhibitor were incubated for 40 min with a protein to inhibitor molar ratio of 1 to 10 (KPC-2 concentration was 10 mg/mL). The KPC-2:inhibitor cocrystals were crystallized using 200 mM lithium sulfate, 100 mM sodium acetate pH 4.4-4.6, and 28-31% PEG8000. After growing for ~3 days, the cocrystals were mounted and cryo-protected with perfluoropolyether (Hampton Research) prior to flash freezing in liquid nitrogen.
Cocrystallization of OXA-24/40 with 3.
OXA-24/40 was preincubated with 3 overnight with a 1:50 molar ratio of protein to inhibitor. The OXA-24/40:3 complex was crystallized in 0.2 M calcium acetate, 0.2 M sodium cacodylate pH 6.5, and 18% PEG8000. Crystals were cryo-protected using the mother liquor before freezing in liquid nitrogen prior to data collection.
X-ray Data Collection and Crystallographic Refinement.
Data for the KPC-2:1, 2, and 3 complexes were collected at the SSRL beamline. The data for the OXA-24/40:3 complex were collected at APS. All data sets were processed using AutoXDS scripts, 42, 43 and the protein structures were refined using Refmac 44 and Coot programs. 45 The starting protein coordinates for all KPC-2 structures in this study were KPC-2 in complex with 3-NPBA (PDB ID: 3RXX) and for the OXA-24/40 starting structure was 4WM9. The KPC-2 structures have two molecules in the asymmetric structure, whereas there is only 1 molecule in the asymmetric unit in the OXA-24/40 structure. The structures in the two different molecules in each KPC-2 complex structure are very similar so, for the most part, only molecule A will be discussed. The chemical structures of inhibitors and their corresponding parameter and topology files were generated using the PRODRG program. 46 The coordinates were checked using the structure validation program PROCHECK 47 and found to have no outliers in the Ramachandran plot. The coordinates and structure factors of the structures have been deposited with the Protein Data Bank, and the PDB identifiers are listed in Table S1 .
Susceptibility Testing.
MICs for various bacterial isolates were determined by broth microdilution method using custom frozen panels (ThermoFisher Scientific, Cleveland, OH) according to the Clinical and Laboratory Standards Institute guidelines. 48, 49 Compounds 1-3, avibactam, relebactam, meropenem, and cefepime were tested alone. Compounds 1-3 were tested at 4 and 8 mg/L, and avibactam and relebactam were tested at 4 mg/L in combination with increasing concentrations of meropenem and cefepime. MICs were performed in triplicate, and modal values are reported.
Murine Peritonitis Model.
Male and female Swiss albino mice were intraperitoneally infected with a bacterial inoculum (3.5 × 10 5 to 3 × 10 6 CFU/mouse) resuspended in 5% hog gastric mucin that resulted in mortality of untreated animals within 24 h. Subcutaneous treatment of drugs was initiated 1 h postinfection for 1 day. Cefepime, cefepime-2, meropenem-cilastatin, meropenem-cilastatin-3, and tigecycline were given as two doses (3 h apart), and colistin was given three doses (3 h apart). Survival patterns were monitored for 7 days. The PD 50/90 values were determined by probit analysis. All animal experiments performed in the manuscript were conducted in compliance with Wockhardt Research Centre guidelines.
Neutropenic Murine Lung Infection Model.
Male and female Swiss mice weighing 25-27 g were rendered neutropenic by intraperitoneal administration of cyclophosphamide (150 and 100 mg/kg; 1 and 4 days prior to infection). Two hours prior to the initiation of antimicrobial therapy, intranasal infection was caused by instilling 80 μL of bacterial suspension (10 5 -10 6 log 10 CFU/mL) of Indian clinical isolate A. baumannii SL04 expressing bla . A group of 6 mice were administered humanized doses of cefepime, 2, and meropenem:cilastatin by subcutaneous route in fractionated regimen. Compound 3 was also administered as fractionated doses in combination with meropenem:cilastatin. Imipenem:cilastatin and relebactam were administered at their simulated clinical doses. Doses were fractionated as q2h regimen.
Lungs from all of the animals including untreated animals were harvested 3 h post last dose of q2h regimen and individually homogenized (Homogenizer, IKA Ultra-Turrax T-25) in 3 mL of normal saline. One hundred microliters of this homogenate was diluted serially and plated on trypticase soy agar plates, and the colonies appearing following incubation at 37 °C for 18 h were counted. Bacterial load of untreated animals enumerated at the time of initiation of therapy (2 h post infection) served as a reference count to quantify the magnitude of antibacterial effect realized through various dosing regimens. Bacterial load at initiation of treatment (2 h post infection) was 6.13 ± 0.17 log 10 CFU/lung, which increased to 7.62 ± 1.22 log 10 CFU/lung at 27 h post infection. All animal experiments performed in the manuscript were conducted in compliance with Wockhardt Research Centre guidelines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (A) Scheme representing the interactions of β-lactamases with DBOs. In this model, formation of the noncovalent complex, enzyme:inhibitor (E:I) is represented by the dissociation constant, K d , which is equivalent to k −1 /k 1 . k 2 is the first order rate constant for the acylation step or formation of E-I. k −2 is the first order rate constant for the recyclization step or reformation of E:I. Reported rarely to date, some DBOs undergo a desulfation reaction; k 3 is the first order rate constant for desulfation to form E:I*, where I* is the desulfated DBO. The desulfated DBO may undergo complete hydrolysis; the hydrolysis, which forms free E and product (P) is represented by the first order rate constant k 4 . (B)
Chemical representation of (A) using avibactam. (C) Acyl-transfer mass spectrometry with 3 (left), 2 (center), and 1 (right). Each DBO was preincubated with KPC-2 at a 1:1 E:I ratio for 1 min (data in top panels in blue) and used for mass spectrometry; then, TEM-1 was added, incubated for 15 s or 5 min (data in center and bottom panels in red), and used for mass spectrometry. 
